Month: December 2022

FIVE Hotels and Resorts is the first hotel group to earn the UL Verified SPIRE Smart Buildings Rating.

NORTHBROOK, Ill., Dec. 1, 2022 /PRNewswire/ — UL Solutions, a global leader in applied safety science, today announced that FIVE Hotels and Resorts’ FIVE Palm Jumeirah and FIVE Jumeirah Village hotels in Dubai are the first hotels to receive UL Verified SPIRE Smart Buildings Ratings. The rating for each building is based on the SPIRE Smart Building Assessment, an evaluation for smart buildings that results in an overall UL Verified SPIRE Smart Buildings Rating.

The FIVE Palm Jumeirah and FIVE Jumeirah Village hotels each received a three-star UL Verified SPIRE Smart Buildings Rating — among the highest-performing program ratings to date for any building category.

“By becoming the first in the luxury hotel space to achieve SPIRE Smart Building Ratings, FIVE Hotels has taken a significant step in validating and demonstrating smart building innovation at two of their landmark properties,” said Sudhi Sinha, vice president of Ecosystems and Service Development group for UL Solutions. “Hotels are complex ecosystems to manage, often with multiple priorities. By assessing, validating and rating key hotel elements that consider the entirety of a smart building, the UL Verified SPIRE Smart Buildings Rating supports FIVE Hotels’ commitment to enhancing sustainability and building performance that improve the overall guest experience and help increase asset value. We thank them for putting their trust in UL Solutions to deliver on that promise.”

The FIVE Palm Jumeirah and FIVE Jumeirah Village hotels received an in-depth, on-site and virtual audit of each of the building’s assets, technologies and processes. To assess for the SPIRE Smart Buildings Ratings, UL Solutions focused on six key, industry-driven building criteria categories that define the full scope of smart building performance, including power and energy, health and well-being, life and property safety, connectivity, cybersecurity and sustainability.

“With the emergence of FIVE as the first hotel group in the world to achieve SPIRE Smart Buildings Ratings for the FIVE Palm Jumeirah and FIVE Jumeirah Village in Dubai, I am humbled by the dedication of the entire FIVE team, which drove environmental and social excellence,” said Kabir Mulchandani, founder and chairman, FIVE Hotels and Resorts. “The FIVE ethos is centered around encouraging a community committed to stewarding world-class sustainability. Therefore, the UL Verified SPIRE Smart Buildings Ratings helped FIVE enhance our sustainability scope to now include seamless cybersecurity, digital connectivity and social safety. We are excited to continue to execute immersive entertainment and luxury lifestyle experiences through a sustainability framework founded on science-driven best practices for smart buildings.”

The SPIRE Smart Buildings program is the first smart building assessment program that offers an independent analysis of the actual performance of a building. SPIRE evaluates buildings against a curated, multifactor framework developed with insights from more than 60 diverse, industry-leading organizations specialized in the buildings industry. The UL Verified SPIRE Smart Buildings Rating helps empower building operators as they consider smart building needs in the face of new and evolving influences. These include the physical assets decarbonization, business and building mission alignment, occupant experiences, cybersecurity concerns, artificial intelligence, image perception, and robotics being introduced into the built environment. In addition, recent health concerns have brought new priorities to building operators looking for smart building systems to help keep occupants safe. SPIRE assessments provide insight into smart building performance and also help communicate a commitment to the health and well-being of its occupants.

About the SPIRE Smart Building Program

The SPIRE Smart Building Program, the world’s first objective assessment and rating program for smart buildings, was created in a partnership between the Telecommunications Industry Association (TIA) and UL Solutions. The SPIRE Smart Building Program provides an assessment of connected technologies within buildings, delivering insights, benchmarks and roadmaps to help lower costs, mitigate risks, create brand differentiation and enhance overall asset value. SPIRE also provides a structured means to assess the outcomes of design for and adoption of smart building technologies.

Visit spiresmartbuildings.ul.com to learn more about the program.

About UL  Solutions
A global leader in applied safety science, UL Solutions transforms safety, security and sustainability challenges into opportunities for customers in more than 100 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers’ product innovation and business growth. The UL Certification Marks serve as a recognized symbol of trust in our customers’ products and reflect an unwavering commitment to advancing our safety mission. We help our customers innovate, launch new products and services, navigate global markets and complex supply chains, and grow sustainably and responsibly into the future. Our science is your advantage.

PRESS CONTACT:
Steven Brewster
UL Solutions
ULNews@UL.com
T: +1 (847) 664.8425

Photo – https://mma.prnewswire.com/media/1959141/FIVE_Hotels_receives_SPIRE_Rating_for_two_properties.jpg

Logo – https://mma.prnewswire.com/media/1849892/UL_Solutions_Logo.jpg

BERLIN, CAIRO and DUBAI, UAE, Nov. 30, 2022 /PRNewswire/ — Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra GmbH, a Berlin-based pharmaceutical company, announced today the signing of an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East (the “Territory”).

According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech’s portfolio of licensed biosimilars once approved, under Bioventure’s exclusive strategic partnership with Alvotech in the region. All other terms and product details in the agreement remain confidential.

Ashraf Radwan, Chief Executive Officer of GlobalOne Healthcare Holding said: “This agreement is another step in our journey to improve access to biopharmaceuticals across the MENA region by driving down their cost. In this way we hope to positively impact healthcare outcomes and patient quality of life, advancing the well-being of the communities we serve.”

Dr. Wafik Bardissi, Chief Executive Officer of Minapharm Pharmaceuticals, said: “Minapharm has provided advanced proprietary technologies to the global biotech industry coupled with end-to-end manufacturing and commercialization expertise for more than two decades. This standout agreement with Bioventure enables selected Alvotech products to boost our regional and continental strategy and elevates access to complex medicines.”

Dr. Lutz Hilbrich, Chief Executive Officer of MiGenTra GmbH, said: “This agreement with Bioventure will allow MiGenTra to provide patients across Africa and the Middle East with a unique set of high quality and affordable biological medicines by combining in-house developed biosimilars with Alvotech’s highly complementary candidates. This deal empowers our belief that Healthcare is a human right and highlights our commitment and long-term vision to transform healthcare in the region.”

Licensed biosimilar candidates cover a wide range of therapeutic areas, all characterized by high unmet medical need in the Territory.

About Bioventure

Bioventure, a subsidiary of Yas Holding’s Healthcare Division, GlobalOne Healthcare Holding (GHH), specializes in biosimilars and speciality generics, in/out-licensing, tech transfer, and investment in disruptive healthtech, medtech and biotechnology solutions. Bioventure is currently the Middle East and Africa’s exclusive license holder for a comprehensive portfolio of biosimilar candidates developed and manufactured by Alvotech, a global biotech company headquartered in Iceland.

About GlobalOne Healthcare

GlobalOne Healthcare Holding LLC (GHH) operates as the Healthcare Division of Yas Holding LLC. With investments in leading bio-pharmaceuticals and innovative manufacturing solutions, GHH is delivering on its commitment to improve healthcare outcomes and patient quality of life. GHH’s healthcare portfolio focuses on the provision of world-class healthcare services across a range of areas including customised clinical and non-clinical hospital management and healthcare consultancy services. Our companies specialise in biopharma, hospital management, medical supply chain, manufacturing, and occupational health.

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech is headquartered in Iceland and employs over 900 people world-wide, with offices in the U.S., Germany, Switzerland and India. Alvotech’s shares are listed on the Nasdaq U.S. Stock Exchange and Nasdaq Iceland First North market under the symbol ALVO.

About Minapharm Pharmaceuticals

Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically-engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly owned Berlin-based subsidiary, ProBioGen, Minapharm has established an integrated business model making it to-date the only gene-to-market biopharmaceutical company in the region. Minapharm employs a collective workforce of over 1400 and is listed on the Cairo and Alexandria stock exchange (Symbol: MIPH).

About MiGenTra GmbH

MiGenTra was founded in 2021. MiGenTra combines the scientific and manufacturing expertise from both contributing companies, ProBioGen and Minapharm Pharmaceuticals. It is established for product development and commercialization in the field of Biosimilars, Cell- and Gene Therapies (CGT) and Vaccines, capitalizing on the strong development and manufacturing capabilities of ProBioGen and Minapharm as well as on the excellent market position of Minapharm in the region.

Minapharm Contact:

Dina Soliman
Director of Business Development &
Strategic Operations
dsoliman@minapharm.com

MiGenTra Contact:

Frédéric Bouvier
Head Corporate Development,
Business Development & Licensing
frederic.bouvier@migentra.com

Logo – https://mma.prnewswire.com/media/1958557/Combined_Logo.jpg

دبي، الإمارات العربية المتحدة، 30 نونبر/تشرين الثاني 2022 / PRNewswire / — تم الاعتراف مؤخرًا بشركة أسترازينيكا ( https://www.astrazeneca.com )، التابعة لشركة الأدوية والتكنولوجيا الحيوية متعددة الجنسيات، كواحدة من أفضل أماكن العمل في شمال أفريقيا وبلاد الشام لعام 2022. تفوقت أسترازينيكا على مؤشر تجربة الموظفين بثقافتها الفريدة وتطورها المهني القوي والتزامها بالاعتراف بالموظفين وتقديرهم. تشمل بعض نتائج التقييم ما يلي:

• وقال 84% من الموظفين إن الشركة هي صاحب العمل المفضل، مما يعكس التزامها بتعزيز ثقافة الأداء العالي.
• ويشعر 82% من الموظفين بالقيمة والاحترام في مكان عمل الشركة

أفضل أماكن العمل هو بمثابة برنامج شهادات دولي، يعتبر “المعيار البلاتيني” في تحديد أفضل أماكن العمل في جميع أنحاء العالم والاعتراف بها، مما يوفر لأصحاب العمل الفرصة لمعرفة المزيد حول التزام موظفيهم ورضاهم، وتكريم أولئك الذين يقدمون تجربة عمل مميزة تتمتع بأعلى المعايير فيما يتعلق بظروف العمل.

 وفي بيان صادر عن رامي سكاندار، الرئيس القطري للشرق الأدنى والمغرب العربي ، “في أسترازينيكا بالشرق الأدنى والمغرب العربي، نعتقد أن الأشخاص الذين يقفون وراء الأرقام أكثر أهمية من الأرقام، وبدون وجود الأشخاص المناسبين والأقوياء، لن نتمكن أبدًا من المضي قدمًا. ندرك أن موظفينا هم أعظم أصولنا ونلتزم بضمان أن يتمكن كل شخص يختار العمل في شركتنا من الوصول إلى إمكاناته الكاملة وأداء أفضل ما لديه وتقديم مساهمة قيمة للمؤسسة. واليوم أنا فخور بالحفاظ على هذه الجائزة للبنان والأردن والعراق للسنة الخامسة على التوالي، ويسرني أن تفوز الجزائر والمغرب وتونس بالجائزة في أول محاولة مشاركة لها. هذه الجائزة مميزة لأنها تحدد أسترازينيكا كصاحب عمل مفضل ومكان رائع للعمل.”

وصرحت نهى زانون، مديرة الموارد البشرية في الشرق الأدنى وبلاد المغرب العربي، قائلة : “تعلمنا، خلال العامين الماضيين من التحديات، أن الأمر لا يتعلق بالأداء والتطوير فحسب، بل يركز أيضًا على رفاهية موظفينا للتغلب على صراعاتهم وتحدياتهم اليومية، مما يسهل عليهم تحقيق بيئة شاملة وجذابة، حيث يمكنهم التفوق على أنفسهم. فالأمر يتعلق بجذب الأشخاص ذوي المهارات المناسبة والذين يشاركوننا قيمنا والاحتفاظ بهم، ومنحهم الفرصة للتعلم والتطور”.

لمزيد من المعلومات، تفضّل بزيارة www.bestplacestoworkfor.org